Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences Inc (OP:ENSCW)

0.0208 UNCHANGED
Last Price Updated: 12:25 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences Inc

< Previous 1 2 Next >
Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614
Via ACCESSWIRE
Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product
Via ACCESSWIRE
Ensysce Biosciences Announces First Subjects Dosed in Second Human Abuse Potential Study
Via ACCESSWIRE
Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR
Via ACCESSWIRE
Ensysce Biosciences to Present at Benzinga All Access Event on Friday, September 23, 2022
Via ACCESSWIRE
Ensysce Biosciences Announces Results of Special Meeting of Stockholders
Via ACCESSWIRE
Ensysce Biosciences Reminds Shareholders to Vote at Upcoming Special Meeting
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103
Via ACCESSWIRE
Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call
Via ACCESSWIRE
Ensysce Biosciences Debuts Redesigned Company Website to Highlight its TAAP(TM) and MPAR(TM) Technologies and Growing Product Pipeline
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences
Via ACCESSWIRE
Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing
Via ACCESSWIRE
Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call
Via ACCESSWIRE
Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call
~ BE Study of PF614 Represents Critical Progress Toward FDA Approval ~~ Supports the 505(b)(2) Regulatory Path for Clinical Development of PF614 ~SAN DIEGO, CA / ACCESSWIRE / July 27, 2022 / Ensysce... 
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study
~ Trial Designed to Test and Confirm Nasal Opioid Manipulation ~ 
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Secures $8 Million Convertible Note Financing
~ Additional Funding from Investor Cohort Validates Company's Mission ~ 
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform
SAN DIEGO, CA / ACCESSWIRE / June 27, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC) (OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to... 
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting
- Shareholder Meeting to be Held on Thursday, June 23rd at 9:00 AM PT 
From Ensysce Biosciences, Inc.
Via AccessWire
Topics Death Intellectual Property
Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study
~ Nasal Opioid Abuse Being Explored for PF614 ~ 
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results
Corporate Update Call to be Held Tuesday, May 17, 2022 SAN DIEGO, CA / ACCESSWIRE / May 12, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage... 
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Releases 2021 Annual Shareholder Letter
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Ensysce Biosciences, Inc.
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Ensysce Biosciences
Via AccessWire
Dr. Lynn Kirkpatrick, Invited Speaker at SMi 22nd Annual Pain Therapeutics Conference in London UK
SAN DIEGO, CA / ACCESSWIRE / April 20, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to... 
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer
SAN DIEGO, CA / ACCESSWIRE / April 18, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to... 
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call
SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to... 
From Ensysce Biosciences, Inc.
Via AccessWire
Ensysce Biosciences Sets September 2021 Conference Schedule
SAN DIEGO, CA / ACCESSWIRE / August 31, 2021 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company with proprietary technology... 
From Ensysce Biosciences, Inc.
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.